Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress

Figure 3

Phospho-aspirin-2 inhibits EGFR phosphorylation. A: Upper: PA-2 1.5 × IC50 inhibited the expression of p-EGFR in MDA-MB-231 and BT-20 cells. Lower: PA-2 treatment inhibited the expression of p-EFGR in MDA-MB-231 and BT-20 xenografts (p < 0.05). B: Effect of PA-2 at various concentrations on apoptosis in EGFR overexpressing MDA-MB-231 cells or their mock transfected control. Western blot confirmed the overexpression of EGFR and increased levels of p-PI3K. C: PA-2 suppressed ADAM17 levels in MDA-MB-231 and BT-20 cells in vitro and in MDA-MB-231 orthotopic xenografts (p < 0.05). In all panels, immunoblots were performed with β-actin as loading control.

Back to article page